Clinical Trial Update: Study to Evaluate the Treatment Benefits of Probiotic Clostridium Butyricum CBM588® for IBS-D [NA]

View source ↗

Summary

A completed clinical trial evaluating the probiotic Clostridium butyricum CBM588 for diarrhea-predominant irritable bowel syndrome (IBS-D).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• CBM588

Snippet

Sponsor: Liaquat University of Medical & Health Sciences | Conditions: IBS-D (Diarrhea-predominant) | NA | Status: COMPLETED